Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PAB9874 - Provider product page
- Provider
- Abnova Corporation
- Proper citation
- Abnova Corporation Cat#PAB9874, RRID:AB_1675249
- Product name
- FHL2 polyclonal antibody
- Antibody type
- Polyclonal
- Description
- Rabbit polyclonal antibody raised against synthetic peptide of FHL2.
- Storage
- Store at -20°C.Aliquot to avoid repeated freezing and thawing.
Submitted references Genetic analysis of anterior posterior expression gradients in the developing mammalian forebrain.
Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2.
Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.
Kudo LC, Karsten SL, Chen J, Levitt P, Geschwind DH
Cerebral cortex (New York, N.Y. : 1991) 2007 Sep;17(9):2108-22
Cerebral cortex (New York, N.Y. : 1991) 2007 Sep;17(9):2108-22
Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2.
Nair SS, Guo Z, Mueller JM, Koochekpour S, Qiu Y, Tekmal RR, Schüle R, Kung HJ, Kumar R, Vadlamudi RK
Molecular endocrinology (Baltimore, Md.) 2007 Mar;21(3):613-24
Molecular endocrinology (Baltimore, Md.) 2007 Mar;21(3):613-24
Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.
Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, Ellinger J, Metzger E, Schüle R, Buettner R
Cancer research 2006 Dec 1;66(23):11341-7
Cancer research 2006 Dec 1;66(23):11341-7
No comments: Submit comment
Supportive validation
- Submitted by
- Abnova Corporation (provider)
- Main image
- Experimental details
- Western blot using FHL2 polyclonal antibody on HeLa cell extract (10 ug/lane). Lane 1: 0.4 ug/mL , lane 2: plus 16 ug blocking peptide.